Gilead Sciences received all required regulatory approvals for its acquisition of Arcellx and extended the tender offer period through February 11, 2025 at 11:59 PM Eastern. The $225.00 per share cash offer values the cell therapy developer at approximately $460 million fully diluted, with no financing contingency and no change to price or terms.
The Hart-Scott-Rodino waiting period expired without a second request. German and Austrian antitrust authorities issued clearances within the standard thirty-day windows. Gilead filed the 8-K on February 4 confirming all regulatory conditions satisfied and announced the extension in the same release, a procedural step that signals deal close within ten business days barring unexpected shareholder resistance. Arcellx shares have traded within 3% of the offer price since late January, indicating the arb community assigns minimal execution risk.
The acquisition adds Arcellx's CART-ddBCMA platform to Gilead's Kite Pharma cell therapy unit. The lead asset ACLX-001 is a Phase 2 candidate targeting multiple myeloma with dosing data expected in Q2 2025. Gilead has $9.2 billion in cash and marketable securities as of the Q4 2024 balance sheet and faces patent expiration pressure on Biktarvy beginning in 2030. The company deployed $4.3 billion on external R&D through acquisitions and partnerships in 2023 and appears to be accelerating bolt-on deals in oncology and immunology at valuations below $1 billion enterprise value, a shift from the larger platform acquisitions that defined the Kite and Immunomedics transactions.
Tender offer extensions after regulatory clearance are mechanical in small-cap biotech M&A. The extension gives retail holders and final arb positions time to tender, and it resets the acceptance threshold clock for deals structured without a minimum tender condition. Arcellx management recommended acceptance in the original December 23, 2024 proxy, and insider holdings total less than 8%, so governance friction is minimal. The remaining variable is whether Gilead accelerates integration announcements or waits until formal close to signal pipeline prioritization within Kite's broader CAR-T portfolio.
Watch for the final acceptance announcement within five business days of the February 11 deadline, typically filed as an 8-K and press release on the same day. If Gilead secures more than 90% acceptance, a short-form merger will likely follow within two weeks, compressing the settlement timeline for remaining shareholders. Any integration commentary around ACLX-001 dosing schedules or Kite manufacturing capacity would clarify whether this deal represents near-term pipeline fill or a longer development bet.
The deal closes in an environment where small-cap biotech M&A is trading at acquisition multiples below 2019-2021 levels, and strategic buyers are re-entering after two years of capital discipline. Gilead's willingness to transact at this valuation suggests the company sees the window for sub-$500 million platform deals narrowing as public biotech indices recover and private equity re-enters earlier-stage oncology assets.